86 146

Cited 0 times in

Intralymphatic immunotherapy with tyrosine-adsorbed allergens: a double-blind, placebo-controlled trial

 Hye Jung Park  ;  Sae-Hoon Kim  ;  Yoo Seob Shin  ;  Chul Hwan Park  ;  Eun-Suk Cho  ;  Seung Joon Choi  ;  So Hyun Park  ;  Joo Hyun Jung  ;  Il Gyu Kang  ;  Myoung Seok Lee  ;  Dae Woo Kim  ;  Sang Min Lee  ;  Min-Suk Yang  ;  Sang Pyo Lee 
 RESPIRATORY RESEARCH, Vol.22(1) : 170, 2021-06 
Journal Title
Issue Date
Adverse events ; Allergen immunotherapy ; Allergic rhinitis ; Intralymphatic injection ; Treatment efficacy
Background: Most previous studies used aluminum hydroxide-absorbed allergen extracts in evaluating the potential therapeutic roles of intralymphatic allergen-specific immunotherapy (ILAIT). In this study, we evaluated the therapeutic efficacy and safety of ILAIT with L-tyrosine-adsorbed allergen extracts of Dermatophagoides farinae, D. pteronyssinus, cat, dog, or mixtures thereof, in patients with allergic rhinitis induced by these allergens.

Methods: In this randomized, double-blind, placebo-controlled trial, study subjects received three intralymphatic injections of L-tyrosine-adsorbed allergen extracts (active group) or saline (placebo group) at 4-week intervals.

Results: Although ILAIT reduced daily medication use and skin reactivity to HDM and cat allergens at 4 months after treatment, overall symptom score on a visual analog scale (VAS), sinonasal outcome test-20 (SNOT-20), rhinoconjunctivitis quality of life questionnaire (RQLQ), daily symptom score (dSS), daily medication score (dMS), daily symptom medication score (dSMS), nasal reactivity to HDM allergen, and basophil activity to HDM, cat, and dog allergens at 4 months and 1 year after treatment were similar between the treatment and control groups. Intralymphatic injection was more painful than a venous puncture, and pain at the injection site was the most frequent local adverse event (12.8%); dyspnea and wheezing were the most common systemic adverse events (5.3%).

Conclusions: ILAIT with L-tyrosine-adsorbed allergen extracts does not exhibit profound therapeutic efficacy in allergic rhinitis and can provoke moderate-to-severe systemic reactions and cause pain at the injection site.

Trial registration: clinicaltrials.gov: NCT02665754; date of registration: 28 January 2016.
Files in This Item:
T202102059.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers
Yonsei Authors
Park, Chul Hwan(박철환) ORCID logo https://orcid.org/0000-0002-0004-9475
Park, Hye Jung(박혜정) ORCID logo https://orcid.org/0000-0002-1862-1003
Cho, Eun Suk(조은석)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.